Patents by Inventor Alexander von Gabain
Alexander von Gabain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8795690Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.Type: GrantFiled: November 26, 2012Date of Patent: August 5, 2014Assignee: Valneva Austria GmbHInventors: Beatrice Tschanun, Eszter Nagy, Andreas Meinke, Alexander Von Gabain, Barbara Maierhofer, Ulrike Stierschneider, Manfred Berger, Christina Neubauer, Katherine Cohen
-
Publication number: 20140212448Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: ApplicationFiled: December 11, 2013Publication date: July 31, 2014Applicant: VALNEVA AUSTRIA GMBHInventors: SHARMILA BAKSHI, THOMAS CIPPS, MARKUS HANER, JUTTA PIKALO, CHRISTINA SATKE, ESZTER NAGY, URBAN LUNDBERG, DAGMAR ZIERER, ANDREAS MEINKE, BIRGIT NOIGES, ULRIKE STIERSCHNEIDER, ALEXANDER VON GABAIN
-
Patent number: 8637052Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: GrantFiled: July 6, 2012Date of Patent: January 28, 2014Assignee: Valneva Austria GmbHInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander Von Gabain
-
Publication number: 20140017270Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.Type: ApplicationFiled: August 15, 2013Publication date: January 16, 2014Applicant: Intercell Austria AGInventors: Andreas Meinke, Eszter Nagy, Alexander Von Gabain, Manfred Berger, Beatrice Tschanun, Michael Schunn
-
Patent number: 8617574Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: GrantFiled: February 15, 2010Date of Patent: December 31, 2013Assignee: Valneva Austria GmbHInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Publication number: 20130280288Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: April 17, 2013Publication date: October 24, 2013Inventors: ANDREAS MEINKE, ASTRID TEUBENBACHER, BEATRICE TSCHANUN, MANUEL ZERBS, MARKUS HANNER, JUTTA PIKALO, ESZTER NAGY, CARMEN GIEFING-KRELL, ALEXANDER VON GABAIN
-
Publication number: 20130243779Abstract: The present invention relates to a protective peptide of Enterococcus faecalis (E. faecalis) or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing an E. faecalis infection; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: February 4, 2010Publication date: September 19, 2013Applicant: Intercell AGInventors: Eszter Nagy, Beatrice Tschanun, Markus Hanner, Manfred Berger, Andreas Meinke, Alexander Von Gabain, Barbara Murray, Kavindra Singh
-
Patent number: 8529911Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.Type: GrantFiled: July 6, 2007Date of Patent: September 10, 2013Assignee: Intercell Austria AGInventors: Andreas Meinke, Eszter Nagy, Alexander von Gabain, Manfred Berger, Beatrice Senn, Michael Schunn
-
Publication number: 20130230526Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: ApplicationFiled: July 6, 2012Publication date: September 5, 2013Applicant: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Patent number: 8445001Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: GrantFiled: August 3, 2012Date of Patent: May 21, 2013Assignee: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing, Alexander Von Gabain
-
Publication number: 20130011403Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: ApplicationFiled: July 6, 2012Publication date: January 10, 2013Applicant: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Patent number: 8343510Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.Type: GrantFiled: January 10, 2008Date of Patent: January 1, 2013Assignee: Intercell AGInventors: Beatrice Senn, Eszter Nagy, Andreas Meinke, Alexander Von Gabain, Barbara Maierhofer, Ulrike Stierschneider, Manfred Berger, Christina Neubauer, Katherine Cohen
-
Publication number: 20120294881Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Applicant: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Kröll, Alexander Von Gabain
-
Patent number: 8303961Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.Type: GrantFiled: March 2, 2012Date of Patent: November 6, 2012Assignee: Intercell AGInventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander Von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
-
Patent number: 8241643Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: GrantFiled: March 17, 2009Date of Patent: August 14, 2012Assignee: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Krōll, Alexander Von Gabain
-
Patent number: 8236326Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection.Type: GrantFiled: April 29, 2008Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Publication number: 20120184710Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.Type: ApplicationFiled: March 2, 2012Publication date: July 19, 2012Applicant: INTERCELL AGInventors: URBAN LUNDBERG, ANDREAS MEINKE, ESZTER NAGY, ALEXANDER VON GABAIN, BIRGIT NOIGES, DIETER GELBMANN, ALBINA POLJAK, CHRISTINE TRISKA
-
Publication number: 20120141487Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Moraxella catarrhalis (Meat) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Moraxella catarrhalis species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell which expresses such antigen. More specifically, such antigens are produced by or associated with bacterial infections caused by Moraxella catarrhalis.Type: ApplicationFiled: May 28, 2010Publication date: June 7, 2012Applicant: Intercell AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Julia Flor, Birgit Noiges, Wolfgang Schueler, Ulrike Schirmer, Verena Salletmayer, Mario Aistleithner, Stefan Seidel, Martin Oleksiewicz
-
Patent number: 8129165Abstract: The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibodType: GrantFiled: September 14, 2007Date of Patent: March 6, 2012Assignee: Intercell AGInventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
-
Publication number: 20120045457Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: ApplicationFiled: February 15, 2010Publication date: February 23, 2012Applicant: INTERCELL AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz